65results about How to "Reduce inflammatory damage" patented technology

The invention discloses a naphthyl sulfamide amino acid derivative, a preparation method and medical application thereof. A naphthyl sulfamide amino acid derivative R3 substituent group represents a substituent group with an amino acid structure; the amino acid structure refers that the substituent group at least contains one carboxyl and one secondary amine or tertiary amine, and the substituentgroup is connected onto a mother nucleus through the secondary amine or the tertiary amine. The naphthyl sulfamide amino acid derivative provided by the invention can interfere with Keap1-Nrf2 combination and activate Nrf2, so that inflammatory injury is reduced, an inflammation microenvironment is improved, and the naphthyl sulfamide amino acid derivative has potential anti-inflammatory activity.The technician in the field knows that an Nrf2 activating agent can be used for inhibiting inflammatory reaction of diseases, so that the compound provided by the invention can be used for preparingan anti-inflammatory drug for treating diseases associated with inflammation, including chronic obstructive pulmonary diseases, Alzheimer diseases, Parkinson, atherosclerosis, chronic renal diseases,diabetes, intestinal inflammation, rheumatoid arthritis and the like.

The present invnetion relates to a Chinese medicine for curing chronic bronchitis, and is made up by using 16 Chinese medicinal materials of bupleurum root, peach kernel, bitter organe, safflower, white peony root, Chinese angelica root, lygusticum root and others. Said Chinese medicine is a kind of honey pill preparation, and possesses the functions of promoting blood icrculation, removing stasis, moistening the lung, transforming phlegm and raising immunity of human body. Its total effective rate is 98.68%, and ita has no obvious toxic side effect.

The invention relates to an anti-acne and restoration solution. The anti-acne and restoration solution comprises, by weight, 0.5-5% of licorice root extract, 0.5-5% of Herba Taraxaci extract, 0.5-5% of honeysuckle flower extract, 0.5-5% of Scutellaria baicalensis root extract, 0.5-5% of sophora flavescens root extract, 0.0001-0.001% of a cell growth factor, 2-5% of horse oil, 3-6% of castor oil, 2-3% of ethanol, 5-10% of glycerin, 5-10% of propylene glycol, 1-5% of a surfactant, 0.01-0.6% of an antiseptic, and the balance of water. All traditional Chinese medicinal extracts, the cell growth factor and the horse oil are reasonably combined to synergistically realize anti-inflammation, bacteriostasis, grease secretion adjustment, cell neogenesis and reconstruction promotion as a skin restoration agent in order to achieve the anti-acne and scar fading purposes. The invention also provides a preparation method of the anti-acne and restoration solution. The preparation method effectively protects activity of effective components in the above composition and makes the anti-acne and scar fading effects of the solution be substantial.

The invention relates to a method for improving the anticancer activity for Codonopsis lanceolata Benth.et Hook.F, which comprises: slicing or homogenizing fresh Codonopsis lanceolata Benth.et Hook.F, or crushing dry Codonopsis lanceolata Benth.et Hook.F, or powdering the dry Codonopsis Lanceolata Benth.et Hook.F; soaking in water; sterilizing under a high pressure; adding 0.5 to 5.0 percent of active yeast and 1 to 8 percent of glucose under a sterile condition when the temperature lowers to 30 DEG C; fermenting at 20 to 37 DEG C for 1 to 10 days, and adding a polar solvent after fermentation to extract for 5 to 24 hours at 0 to 100 DEG C; and filtering, recovering solvent and concentrating under reduced pressure or drying by freezing. The method can improve the inhibition effect of Codonopsis lanceolata Benth.et Hook.F on the growth of tumors.

The invention belongs to the technical field of immunotherapy, and discloses a medicine for treating or adjunctively treating new coronapneumonia, the medicine can activate SLAMF7, and the expressionlevel of inflammatory factors generated by stimulating PBMC by new coronavirus protein can be obviously inhibited by activating the SLAMF7. According to the invention, SLAMF7 is used as a target for diagnosis/immunotherapy of new coronavirus pneumonia for the first time. New coronal pneumonia can be diagnosed by detecting the expression of SLAMF7 in mononuclear macrophages. Immunotherapy of new coronavirus pneumonia can be achieved by utilizing the SLAMF7 recombinant protein and the immunotherapy method thereof, and the method has the advantages of slowing down inflammatory factor storm, relieving inflammatory injury and the like, and is suitable for comprehensive treatment of new coronavirus pneumonia.

The invention disclosed a kind of medicine that can treat hemorrhagic shock, especially a kind of blood plasma substitute which contains one active ingredient. The ingredient can not only expand the blood volume, it can also improve the blood rheology and relieve inflamed damage. The blood plasma substitute which has the two functions is provided in the invention. There's also provided a active ingredient which is a physically acceptable polyose high molecular compound. The active ingredient is prepared by raw plant such as astragali radix. The blood plasma substitute in the invention can be used as medicine to treat hemorrhagic shock.

The invention discloses a Mongolia astragalus pathogenesis-related protein, a crystal thereof, a growth method and an application. The Mongolia astragalus pathogenesis-related protein has any amino acid sequence of (a) to (c), (a) is an amino acid sequence as shown in SEQ ID NO. 1, (b) is an amino acid sequence with at least 90% of homology of the amino acid sequence as shown in SEQ ID NO. 1, or is a homologous compound, derivative and fragment or mutant without losing biological activity of the amino acid sequence as shown in (a) or (b). According to the Mongolia astragalus pathogenesis-related protein, the amino acid sequence of AmPR-10 is firstly disclosed, identification and functional study of the AmPR-10 are facilitated, the application of the AmPR-10 in preparation of a medicine fortreating idiopathic pulmonary fibrosis is further discovered, treatment effects of the AmPR-10 are obvious, the AmPR-10 serves as an extract of natural Chinese herbal medicines, so that the AmPR-10 is wide in source, low in toxicity and suitable for clinical application.

The invention discloses a Mongolian medicament for preventing and treating bovine mastitis. The Mongolian medicament consists of picrorhiza rhizome, Chinese rhubarb, borneol, cape jasmine fruit, turmeric, medicine terminalia fruit and szechwan Chinaberry fruit, wherein each component accounts for 10-20 percent by weight of total amount of the Mongolian medicament. The Mongolian medicament for preventing and treating bovine mastitis can be used for effectively improving the specificity and nonspecific immunity of a milk cow suffering from recessive mastitis, recovering milk component to almostnormal state or normal state and solving the problem of residual of antibiotics in milk during treatment, has a remarkable curative effect, and is an environmentally-friendly medicament which is usedfor treating bovine mastitis and has anti-inflammatory and immune effects.

The invention relates to the technical field of biomedical engineering, and provides ACE2 immune fusion protein and application thereof. A structural general formula of the ACE2 immune fusion proteinis Z1-Z2, wherein Z1 is ACE2 or a functional variant or fragment thereof, and Z2 is an IgA heavy chain constant region or a functional variant or fragment thereof. Experiments prove that the ACE2-IgAimmune fusion protein enhances the ACE2 enzyme activity, effectively enhances the anti-immune cell IgA receptor activation, enhances the ACE2-dependent immune cell phagocytosis and clearance effects and lowers the immune cell secretion effect, and ACE2-IgG type fusion protein has no similar effect. Through animal model experiments, the immune fusion protein can reduce overexpression release of organ inflammatory mediators, relieve organ inflammatory injury, enhance organ anti-stress ability and resist organ injury. Through independent application or combination with other related disease drugs, inflammatory mediator related diseases caused by ACE2 down-regulation and/or dysfunction can be effectively treated, and wide clinical application prospects are achieved.

The invention relates to the technical field of biomedical engineering, provides an ACE2 protein and IL6 or TNF alpha antagonist composition and an application thereof, and particularly an applicationof an ACE2 protein and any one or two of an IL-6 antagonist and a TNF alpha antagonist to preparation of a medicine for treating inflammatory mediator disorder related diseases mediated by ACE2 expression level or function exceptions. The medicine is a medicine composition taking the ACE2 protein and any one or two of the IL6 antagonist and the TNF alpha antagonist as active components, or is a fusion polypeptide formed by the ACE2 protein and any one or two of the IL6 antagonist and the TNF alpha antagonist. The composition or the formed fusion polypeptide can accidentally mediate the ACE2 dependent immune cell clearing effect, reduce the ADE effect of ACE2Ig and reduce the immune cell secretion effect. In an animal model, overexpression release of organ inflammatory mediators can be reduced, organ inflammatory injury can be reduced, the anti-stress capability of organs can be enhanced, and organ injury can be resisted.

The invention discloses a compound with an indoline skeleton, and a preparation method and medical application of the compound. The compound containing the indoline skeleton provided by the inventioncan interfere with Keap1-Nrf2 interaction activate Nrf2 and a downstream factor, reduce cell inflammatory factors and enhance cell oxidation resistance; and therefore, the compound can reduce inflammatory injuries, has potential anti-inflammatory activity, and can be used for preparing anti-inflammatory drugs for treating inflammatory injuries caused by a plurality of inflammation-related diseases, including myocarditis, chronic obstructive pulmonary disease (COPD), Alzheimer's disease, Parkinson's disease, atherosclerosis, chronic kidney disease (CKD), diabetes, intestinal inflammation, rheumatoid arthritis and the like.

The invention relates to the technical field of shampoo products, in particular to a plant anti-dandruff composition as well as a silicone-oil-free shampoo and a preparation method thereof. The plantanti-dandruff composition is composed of a curcuma kwangsiensis extract, a curcuma wenyujin extract and a nymphaea caerulea flower extract and is added to the silicone-oil-free shampoo, and the pure vegetable anti-dandruff and itching effect is achieved; and the shampoo has the advantages of being natural, mild, non-irritant and high in safety. The silicone-oil-free shampoo has the effects of regulating scalp grease secretion and killing and inhibiting malassezia breeding, and the dandruff problem is solved from the source of dandruff generation. The preparation method of the silicone-oil-freeshampoo has the characteristics of simple process, low production cost and suitability for large-scale production. The plant anti-dandruff composition is one or a composition of more than two of thecurcuma kwangsiensis extract, the curcuma wenyujin extract and a nymphaea tetragona or nymphaea caeruleaflower extract, and has the effects of regulating scalp grease secretion and killing and inhibiting malassezia breeding, so the dandruff problem can be solved from the source of dandruff generation.

The invention belongs to the field of traditional Chinese medicines, and in particularly relates to an application of radix bupleuri polysaccharide in preparing a medicine for preventing and treating flu and virus-induced acute lung injury. According to the invention, a total polysaccharide extract is separated and extracted from traditional Chinese medicine radix bupleuri, wherein the average yield of the product is 3%, and the content of polysaccharide exceeds 65%. The integral experiment proves that the radix bupleuri total polysaccharide extract has a remarkable treatment effect for the mouse acute lung injury induced by influenza A virus H3N2. Through an anti-inflammatory mechanism thereof, the radix bupleuri polysaccharide inhibits the release and activation of pro-inflammatory cytokines and chemotactic factors, promotes the release of the inflammatory cytokines, inhibits the replication of the virus, and alleviates empsyxis and pulmonary edema, thus reducing acute lung injury. The radix bupleuri polysaccharide can be used for preparing the medicine for preventing and treating vaccinum influenzae vivum and virus pneumonia.

The invention discloses an application of dracocephalum moldavica total flavonoids to preparation of a drug for preventing and treating the AD (Alzheimer's disease). An AD mouse model is established through hypodermic injection of sodium nitrite/D-galactose, the learning and memory capacity and biochemical indexes are scientifically assessed through mouse positioned navigation tests and space exploration tests, it proves that the dracocephalum moldavica total flavonoids can improve the space learning and memory capacity of AD model mice, dose dependence is formed, escape incubation of the AD mice is shortened, and platform crossing times in the space exploration tests are significantly increased; meanwhile, the content of MDA in cortical tissue in the AD mice can be significantly decreased, the content of SOD can be significantly increased, and the oxidative stress level in brain tissue can be reduced; also, through reduction of expression of pro-inflammatory factors IL-1beta and TNF-alpha, inflammatory injuries to the brain tissue can be relieved, the neuron protection role can be played, and the learning and memory capacity of the AD mice can be improved finally. Thus, a reference basis can be provided for clinic application of the dracocephalum moldavica total flavonoids in the future.

The invention discloses a method to construct an animal model to study anti-inflammatory effect of spirulina extract, namely to construct a verification model of mouse acute ear swelling by using xylene as inflammatory agents. The contents of IL-2, IL-6, IL-1 beta, TNF-alpha and IFN-gamma in serum of a model mouse are detected; mouse organ indexes are recorded; pathological tissue slices of thymusand spleen are made; tissue structural changes of the thymus and spleen are observed in terms of histomorphology; anti-inflammatory effect of spirulina extract is evaluated. The study shows that theanti-inflammatory effect can partly increase the IL-2 and IL-6 levels in mice and reduce the IL-1 beta level in mice, plays a certain positive role of restoring TNF-alpha and IFN-gamma in mice to normal levels, and therefore, inhibits related pathological injury processes and relieves inflammatory injury. Therefore, the method can be used to provide basis for the deep development and utilization and clinical application of spirulina.

The invention provides an application of an acanthopanax extract in preparing medicine for preventing or treating cardiac toxicity, and belongs to the field of medicine. The inventor finds that the acanthopanacis senticosi extract can effectively prevent or treat cardiac toxicity caused by adriamycin, can increase myocardial function, improve cardiac configuration and cardiac remodeling, alleviatemyocardial tissue ultrastructure and pathological change, and inhibit apoptosis of damaged myocardial cells and reduce oxidative and inflammatory damage of myocardial cells. The extract can be used for preparing medicine for preventing or treating cardiac toxicity, thereby protecting myocardial cells, avoiding side effects of adriamycin and having wide application prospect.

The invention discloses a compound with a mother nucleus of 3-phenyl-1, 2, 4-oxadiazole as well as a preparation method and application thereof. The provided compound with a mother nucleus of 3-phenyl-1,2,4-oxadiazole is simple in preparation method and novel in structure. The compound can specifically inhibit the activation of NLRP3 inflammasome, so that maturation and secretion of IL-1[beta] are reduced, inflammatory injury is relieved, and the inflammatory micro-environment is improved. Therefore, the compound has remarkable anti-inflammatory activity and has no obvious toxicity to THP-1 cells. The disclosed compound can be prepared into an anti-inflammatory drug and used for treating inflammation-related diseases, including diabetes, atherosclerosis, rheumatic arthritis, rheumatoid arthritis, chronic blocking lung diseases, gout, chronic kidney diseases, neurodegenerative diseases, cryopyrin-associated periodic syndromes, non-alcoholic fatty liver disease, and inflammatory intestinal diseases.

The invention discloses a compound with pyridoimidazole as a parent nucleus as well as a preparation method and application of the compound. The compound with the mother nucleus being pyridoimidazole is novel in structure and simple in preparation method, can specifically inhibit activation of NLRP3 inflammasomes and reduce mature secretion of interleukin IL-1beta, so that inflammatory injury is relieved, the inflammatory microenvironment is improved, and the compound has remarkable anti-inflammatory activity and has no obvious toxicity to THP-1 cells. The compound provided by the invention can be prepared into an anti-inflammatory drug and used for treating inflammation-related diseases, including rheumatic arthritis, rheumatoid arthritis, inflammatory intestinal diseases, gout, atherosclerosis, non-alcoholic fatty liver diseases, cold pyraline-related periodic syndromes, chronic kidney diseases, diabetes mellitus, neurodegenerative diseases and the like.